Research ProgramsNew IMP ProductsOur main area of research is on new applications of Immutep's soluble recombinant LAG-3 proteins (technology "ImmuFact®"), LAG-3 fusion proteins (technology "ImmuCcine®") and LAG-3-specific chimeric monoclonal antibodies (technology "ImmuTune®"). © 2002 Immutep, S.A.
|
Press Release
10/2008 - IMP321 IND Allowance in Pancreatic Cancer
Immutep S.A. announced today that the FDA, after review of the ...
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy 
Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer 
Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients 
Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I 
lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...
|
|
